

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number  
21-18502-01

Docket or Reference number  
030-13801

Amendment No. 12

Holland Community Hospital  
602 Michigan Avenue  
Holland, MI 49423

In accordance with letter dated August 7, 1985, License Number 21-18502-01 is amended as follows:

Condition 12. is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Marlen F. Junck, M.D.

Groups I, II and III  
In vitro studies  
Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction

Richard W. Partridge, M.D.

Groups I, II and III  
In vitro studies

Owen Gesink, M.D.

Groups I, II and III  
In vitro studies

Frank C. Campbell, M.D.

Groups I, II and III  
In vitro studies

John D. DeMott, Jr., M.D.

Groups I, II and III  
Iodine-131 treatment of  
hyperthyroidism and cardiac  
dysfunction

Licensed material of the types,  
quantities, and forms specified  
in Sections 35.31(a) of 10 CFR 35  
and 31.11(a) of 10 CFR 31 to be  
used in accordance with the  
provisions of paragraphs (a) and  
(c) of Section 35.31, 10 CFR 35  
and paragraphs (a), (c), and (d)  
of Section 31.11, 10 CFR 31

8509120342 850827  
REG3 LIC30  
21-18502-01 PDR

1/1 COPY 2  
me30  
BS 8/28/85

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

21-18502-01

Docket or Reference number

030-13801

Amendment No. 12

Mark E. Meengs, M.D.

Technetium-99m as listed in  
Groups II and III limited to  
cardiac imaging and function  
studies

Robert W. Jasinski, M.D.

Groups I, II and III  
In vitro studies



For the U.S. Nuclear Regulatory Commission

Date August 27, 1985

Original Signed  
By Evelyn R. Matson  
Materials Licensing Section, Region III  
COPY